Fortrea Holdings Inc. (NASDAQ: FTRE) partners with Emery Pharma for rapid MNP testing in rifampin, ensuring FDA-compliant DDI studies. Rifampin, a commonly used antibiotic, had MNP levels exceeding accepted limits in 2021, leading to an FDA guidance update in 2023. FTRE is a contract research organization offering biopharmaceutical product and medical device development solutions globally.

Read more at Yahoo Finance: Fortrea, Emery Pharma Partner for Rapid MNP Testing in Rifampin, Enables FDA-Compliant DDI Studies